HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
About the study
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Male and female subjects aged ≥2 years with CHI with persistent hypoglycemia despite current SoC treatment according to the investigator's evaluation or documentation
- Stable therapy with SoC medications with or without nutritional supplementation
- Previously undergone near-total pancreatectomy or being treated with a nonsurgical approach, having been evaluated as not eligible for pancreatic surgery
- HbA1c <7%
EXCLUSION CRITERIA
Exclusion Criteria:
- Subjects with type 1 or type 2 diabetes mellitus
- Other reasons for hypoglycemia, including but not limited to drug-induced hyperinsulinemic hypoglycemia, etc
- Treatment of CHI with continuous intravenous glucose or glucagon infusion within 3 months prior to screening
- Subjects with current use of any drugs that are known to interfere with the study drug, glucose metabolism, or study procedures (eg, use of systemic glucocorticoids [excluding topical, intra-articular or ophthalmic application, nasal spray, or inhaled forms] or insulin)
- Have conditions that could affect glucose levels such as pheochromocytoma, insulinoma, and glucagonoma
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Congenital Hyperinsulinism
Age (in years)
2+
Phase
Phase 2
Participants needed
16
Est. Completion Date
Mar 31, 2025
Treatment type
Interventional
Sponsor
Hanmi Pharmaceutical Company Limited
ClinicalTrials.gov identifier
NCT04732416
Study number
HM-GCG-201
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?